The net result was a loss of 5.6% of body weight in semaglutide participants and 0.1% in placebo participants
Cold Spring Harb Perspect Biol 4(12):a007997
ET Saturday, June 6 DALLAS, JUNE 6, 2026 Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism or death when compared to similar adults who were not taking these medications, according to new research published today in the Journal of the American Heart Association , an open-access, peer-reviewed journal of the American Heart Association
For researchers serious about optimizing their weight management protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, detailed tirzepatide dosing guides , and a community of thousands who have navigated these exact questions